This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodríguez-Burford, C. Articles by Grizzle, W. E. Search for Related Content PubMed PubMed Citation Articles by Rodríguez-Burford, C. Articles by Grizzle, W. E. Related Collections Key Article

Effects of Nonsteroidal Anti-Inflammatory Agents (NSAIDs) on Ovarian Carcinoma Cell Lines

Preclinical Evaluation of NSAIDs as Chemopreventive Agents¹

Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Biostatistics Unit [M. N. B., L. I. T., E. E. P.] and Department of Pathology [C. R-B., D. K. O., R. B. M., W. E. G.], The University of Alabama at Birmingham, Birmingham, Alabama 35213

Purpose: Nonsteroidal anti-inflammatory agents may inhibit carcinogenesis in specific tissues including the colon, breast, and pancreas, and, hence, may prove to be effective chemopreventive agents. The purpose of this study was to investigate the cellular effects of acetylsalicylic acid (ASA), acetaminophen, and a COX-2 inhibitor (NS-398) on the growth of cell lines of human ovarian cancer in vitro. Experimental Design: SK-OV-3, Caov-3, and NIH:OVCAR-3 ovarian carcinoma cell lines were treated with ASA (10^-6 M—10^-2 M), acetaminophen (10^-6 M—10^-2 M), and a COX-2 inhibitor (10^-6 M–10^-4 M) for 96 h. The number of viable cells was determined using a tetrazolium conversion assay. Immunohistochemical assessment was performed for alterations in expression of Ki-67, erbB-2, COX enzyme, and apoptosis in primary ovarian cancer cells using terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling assay. Results: A decrease in cell number compared with controls was observed for all of the cell lines treated with ASA, acetaminophen, and COX-2 inhibitor by cell count and tetrazolium conversion assay. A significant decrease in Ki-67 compared with controls in the OVCAR-3 (P = 0.005) and SK-OV-3 (P = 0.007) cell lines after treatment with the COX-2 inhibitor was observed. We observed a decrease in mitotic activity compared with controls in each cell line after treatment with the COX-2 inhibitor. Apoptosis was observed in primary ovarian cancer cell culture treated with COX-2 inhibitor. Conclusion: Our results suggest additional study for the use of nonsteroidal anti-inflammatory agents, specifically COX-2 inhibitors, as a strategy of chemoprevention for ovarian cancer.

Key Article

Mechanisms Underlying Chemoprevention of Ovarian Cancer

Gordon B. Mills
Clin. Cancer Res. 2002 8: 7-10. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				R. P. Rocconi, T. O. Kirby, R. S. Seitz, R. Beck, J. M. Straughn Jr, R. D. Alvarez, and W. K. Huh Lipoxygenase Pathway Receptor Expression in Ovarian Cancer Reproductive Sciences, March 1, 2008; 15(3): 321 - 326. [Abstract] [PDF]

				T. M. Robinson-Smith, I. Isaacsohn, C. A. Mercer, M. Zhou, N. Van Rooijen, N. Husseinzadeh, M. M. McFarland-Mancini, and A. F. Drew Macrophages Mediate Inflammation-Enhanced Metastasis of Ovarian Tumors in Mice Cancer Res., June 15, 2007; 67(12): 5708 - 5716. [Abstract] [Full Text] [PDF]

				Y.-C. SONG, S.-H. KIM, Y.-S. JUHNN, and Y.-S. SONG Apoptotic Effect of Celecoxib Dependent Upon p53 Status in Human Ovarian Cancer Cells Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 26 - 34. [Abstract] [Full Text] [PDF]

				M. Kioi, S. Takahashi, M. Kawakami, K. Kawakami, R. J. Kreitman, and R. K. Puri Expression and Targeting of Interleukin-4 Receptor for Primary and Advanced Ovarian Cancer Therapy Cancer Res., September 15, 2005; 65(18): 8388 - 8396. [Abstract] [Full Text] [PDF]

				T. Daikoku, D. Wang, S. Tranguch, J. D. Morrow, S. Orsulic, R. N. DuBois, and S. K. Dey Cyclooxygenase-1 Is a Potential Target for Prevention and Treatment of Ovarian Epithelial Cancer Cancer Res., May 1, 2005; 65(9): 3735 - 3744. [Abstract] [Full Text] [PDF]

				J. Symowicz, B. P. Adley, M. M.M. Woo, N. Auersperg, L. G. Hudson, and M. S. Stack Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells Cancer Res., March 15, 2005; 65(6): 2234 - 2242. [Abstract] [Full Text] [PDF]

				J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493. [Abstract] [Full Text] [PDF]

				A. L. Lovering, J. P. Ride, C. M. Bunce, J. C. Desmond, S. M. Cummings, and S. A. White Crystal Structures of Prostaglandin D2 11-Ketoreductase (AKR1C3) in Complex with the Nonsteroidal Anti-Inflammatory Drugs Flufenamic Acid and Indomethacin Cancer Res., March 1, 2004; 64(5): 1802 - 1810. [Abstract] [Full Text] [PDF]

				A. F. Badawi, M. B. Eldeen, Y. Liu, E. A. Ross, and M. Z. Badr Inhibition of Rat Mammary Gland Carcinogenesis by Simultaneous Targeting of Cyclooxygenase-2 and Peroxisome Proliferator-activated Receptor {gamma} Cancer Res., February 1, 2004; 64(3): 1181 - 1189. [Abstract] [Full Text] [PDF]

				T. P. Connolly Cyclooxygenase-2 Inhibitors in Gynecologic Practice Clin. Med. Res., April 1, 2003; 1(2): 105 - 110. [Abstract] [Full Text] [PDF]

				M. A. Brewer, K. Johnson, M. Follen, D. Gershenson, and R. Bast Jr. Prevention of Ovarian Cancer: Intraepithelial Neoplasia Clin. Cancer Res., January 1, 2003; 9(1): 20 - 30. [Abstract] [Full Text] [PDF]

				M. N. Barnes, W. E. Grizzle, C. J. Grubbs, and E. E. Partridge Paradigms for Primary Prevention of Ovarian Carcinoma CA Cancer J Clin, July 1, 2002; 52(4): 216 - 225. [Abstract] [Full Text] [PDF]

				G. B. Mills Mechanisms Underlying Chemoprevention of Ovarian Cancer Clin. Cancer Res., January 1, 2002; 8(1): 7 - 10. [Abstract] [Full Text] [PDF]